Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

被引:1
|
作者
Skoeld, Camilla [1 ]
Corvigno, Sara [2 ]
Dahlstrand, Hanna [2 ]
Enblad, Gunilla [1 ]
Mezheyeuski, Artur [3 ]
Sundstroem-Poromaa, Inger [4 ]
Stalberg, Karin [4 ]
Tolf, Anna [1 ]
Glimelius, Ingrid [1 ,5 ]
Koliadi, Anthoula [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[5] Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden
关键词
Ovarian cancer; Parity; Progesterone receptor; Tissue micro array; HORMONE-RECEPTOR EXPRESSION; RISK-FACTORS; PROGESTERONE; ESTROGEN; EPITHELIUM; APOPTOSIS; OVULATION; SURVIVAL;
D O I
10.1007/s10552-024-01876-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose High-grade serous ovarian cancer (HGSC) is the most common ovarian cancer subtype. Parity is an important risk-reducing factor, but the underlying mechanism behind the protective effect is unclear. Our aim was to study if the expression of hormones and proteins involved in pregnancy were affected by the woman's parity status, and if they may be associated with tumor stage and survival.Methods We evaluated expression of progesterone receptor (PR), progesterone receptor membrane component 1 (PGRMC1), relaxin-2, and transforming growth factor beta 1 (TGF beta 1) in tumor tissue from 92 women with HGSC parous (n = 73) and nulliparous (n = 19). Key findings were then evaluated in an independent expansion cohort of 49 patients. Survival rates by hormone/protein expression were illustrated using the Kaplan-Meier method. The independent prognostic value was tested by Cox regression, using models adjusted for established poor-prognostic factors (age at diagnosis, FIGO stage, type of surgery, and macroscopic residual tumor after surgery).Results HGSC tumors from parous women were PR positive (>= 1% PR expression in tumor cells) more often than tumors from nulliparous women (42% vs. 16%; p-value 0.04), and having more children was associated with developing PR positive tumors [i.e., >= 3 children versus nulliparity, adjusted for age at diagnosis and stage: OR 4.31 (95% CI 1.12-19.69)]. A similar result was seen in the expansion cohort. Parity status had no impact on expression of PGRMC1, relaxin-2 and TGF beta 1. No associations were seen with tumor stage or survival.Conclusion Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
引用
收藏
页码:1101 / 1109
页数:9
相关论文
共 50 条
  • [21] The role of Apela in high-grade serous ovarian cancer
    Daily, Laura R.
    Ganguly, Debolina
    Hayes, D. Neil
    Wang, Yinan
    Sims, Michelle M.
    Cheng, Jinjun
    ElNaggar, Adam C.
    Pfeffer, Lawrence M.
    CANCER RESEARCH, 2018, 78 (13)
  • [22] CHARACTERIZATION OF TUMOR SPHEROIDS FROM HIGH-GRADE SEROUS OVARIAN CANCER BASED ON MORPHOLOGICAL FEATURES AND CELL COMPOSITION
    Miceska, Simona
    Skof, Erik
    Gasljevic, Gorana
    Prevodnik, Vernoika Kloboves
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A265 - A266
  • [23] Drugs Repurposing in High-Grade Serous Ovarian Cancer
    Torralba, Manuel
    Farra, Rossella
    Maddaloni, Marianna
    Grassi, Mario
    Dapas, Barbara
    Grassi, Gabriele
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
  • [24] Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Morse, Christopher B.
    Norquist, Barbara M.
    Harrell, Maria I.
    Agnew, Kathy J.
    Gray, Heidi J.
    Urban, Renata R.
    Garcia, Rochelle L.
    Goff, Barbara A.
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 389 - 392
  • [25] Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Morse, C.
    Norquist, B.
    Bernards, S.
    Harrell, M.
    Agnew, K.
    Swisher, E.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 196 - 196
  • [26] MOLECULAR AND FUNCTIONAL HETEROGENEITY OF CANCER ASSOCIATED FIBROBLASTS IN HIGH-GRADE SEROUS OVARIAN CANCER
    Hussain, Ali
    Voisin, Veronique
    Poon, Stephanie
    Meens, Jalna
    Dmytryshyn, Julia
    Paterson, Josh
    Bernardini, Marcus
    Bader, Gary
    Neel, Benjamin G.
    Ailles, Laurie E.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 134 - 134
  • [27] Immune cell landscapes are associated with high-grade serous ovarian cancer survival
    Zhang, Guoan
    Zhang, Yan
    Zhang, Jingjing
    Yang, Xiaohui
    Sun, Wenjie
    Liu, Ying
    Liu, Yingfu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
    Azzalini, Eros
    Stanta, Giorgio
    Canzonieri, Vincenzo
    Bonin, Serena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [29] High-grade Anaplastic Transformation of Ovarian Serous Borderline Tumor
    Zhang, Xiaoming
    Devereaux, Kelly A.
    Ryan, Emily
    Fei, Fei
    Kunder, Christian A.
    Longacre, Teri A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024, 48 (11) : 1395 - 1407
  • [30] The phenotype of tumor-associated macrophages in human high-grade serous ovarian carcinoma
    Larionova, I.
    Kazakova, E. O.
    Iamshchikov, P.
    Rakina, M.
    Kzhyshkowska, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1192 - S1192